Axon Enterprise (NASDAQ:AXON) Price Target Raised to $525.00 at Needham & Company LLC

Axon Enterprise (NASDAQ:AXON) had its target price raised by investment analysts at Needham & Company LLC from $400.00 to $525.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price target would indicate a potential upside of 18.25% from the company’s current price.

Several other analysts have also issued reports on AXON. Jefferies Financial Group assumed coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price on the stock. Craig Hallum upped their price objective on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. JMP Securities upped their price objective on Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Robert W. Baird upped their price objective on Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Finally, Barclays upped their price objective on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $375.00.

Axon Enterprise Stock Up 1.4 %

NASDAQ:AXON opened at $443.98 on Tuesday. Axon Enterprise has a 1 year low of $199.29 and a 1 year high of $444.16. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The stock has a market cap of $33.55 billion, a price-to-earnings ratio of 117.15, a PEG ratio of 11.74 and a beta of 0.94. The stock has a 50-day moving average price of $388.71 and a two-hundred day moving average price of $331.95.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The firm had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company’s revenue was up 34.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.80 earnings per share. As a group, equities analysts expect that Axon Enterprise will post 1.79 earnings per share for the current year.

Insider Buying and Selling

In other Axon Enterprise news, CEO Patrick W. Smith sold 80,300 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the transaction, the chief executive officer now owns 3,015,366 shares in the company, valued at $1,121,052,771.48. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Axon Enterprise news, CEO Patrick W. Smith sold 80,300 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the transaction, the chief executive officer now owns 3,015,366 shares in the company, valued at $1,121,052,771.48. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Patrick W. Smith sold 70,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $362.21, for a total value of $25,354,700.00. Following the transaction, the chief executive officer now owns 2,945,366 shares in the company, valued at approximately $1,066,841,018.86. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 371,172 shares of company stock valued at $137,000,162. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently modified their holdings of the business. Mather Group LLC. increased its stake in shares of Axon Enterprise by 3.7% in the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 27 shares during the last quarter. CWM LLC increased its stake in shares of Axon Enterprise by 1.3% in the 3rd quarter. CWM LLC now owns 2,856 shares of the biotechnology company’s stock valued at $1,141,000 after purchasing an additional 36 shares during the last quarter. SPC Financial Inc. increased its stake in shares of Axon Enterprise by 2.2% in the 3rd quarter. SPC Financial Inc. now owns 1,773 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 38 shares during the last quarter. Dorsey Wright & Associates increased its stake in shares of Axon Enterprise by 0.3% in the 2nd quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company’s stock valued at $4,135,000 after purchasing an additional 39 shares during the last quarter. Finally, Avantax Advisory Services Inc. increased its stake in shares of Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after purchasing an additional 40 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.